SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Briefs

Inside Views

Contribute your views! Submit an Inside Views idea to info [at] ip-watch [dot] ch.

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Call For Transparency In The Trans-Pacific Partnership Negotiation

In this post, three US law professors explain a recent call by over 30 legal scholars for the US Trade Representative to increase transparency for the Trans-Pacific Partnership Agreement intellectual property chapter, and their response to Ambassador Kirk’s response that he is “strongly offended” by the suggestion that the negotiation is not adequately transparent already.





Latest Comments
  • Congratulations upon re-election;-WHO chief.Priori... »
  • Great article. Ms. Chan may want to read our book ... »

  • For IPW Subscribers
    A guide to Geneva-based public health and intellectual property organisations. Read More >

    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >


    World Health Assembly Adopts Milestone R&D Resolution

    Published on 27 May 2006 @ 5:54 pm

    By for Intellectual Property Watch

    The World Health Assembly today agreed to establish an intergovernmental group to develop a global plan on research and development for diseases predominantly affecting developing countries. The agreement reflects a bridging of significant gaps between parties on the issue a few weeks ago.

    The resolution was adopted in 90 seconds with no debate, a developed country official said. Sources gave credit to developing countries, in particular Kenya, as well as the cooperative spirit of the United States for the agreement.

    The adopted resolution was based on a working paper (A59/A/Conf. Paper No. 8) which was agreed to on 26 May by a technical group set up at the 22-27 May World Health Assembly. The paper is entitled: “Public health, innovation, essential health research and intellectual property rights: towards a global strategy and plan of action.”

    The final resolution combines two previous draft resolutions: One based on a Brazil and Kenya suggestion for a global framework on essential health research and development (EB117 R13), and another draft resolution based on the recommendations in a report from the World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health (CIPIH). Its main suggestion was the setting up of a global plan of action, derived from its report published in April (IPW, Public Health, 3 April 2006).

    Today’s adopted resolution establishes an intergovernmental working group open to all member states to “draw up a global strategy and plan of action in order to provide a medium-term framework based on the recommendations of the commission.” This is similar to wording in the CIPIH report.

    It further suggests that the strategy and plan of action should secure “an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries.” Priorities and funding needs also should be identified, it states.

    The final resolution does not contain language on it being “legally binding” as proposed in the original draft of Brazil and Kenya.

    The working group is to report to the 60th World Health Assembly, to be held in one year from now, with the final plan completed by the 61st assembly. The resolution also invites representatives from non-governmental and intergovernmental organisations and others to act as observers of the working group, according to the paper.

    Reactions Positive

    One developed country official who participated in the technical group was pleased afterward at the resolution’s passage. “We are glad we could agree on this working group and its mandate” and that it will be “open to observers and experts,” the official said. The official added the hope that the resolution would bring quick results.

    The official also said that the “medium-term” phrase was a compromise for the word “framework” which was carried forward from the draft resolution from Brazil and Kenya, and which all along has been a very controversial issue. Some officials had argued in the technical working group that the word “framework” was a disguise for a “treaty” but Kenya had stressed that by framework it did indeed mean framework, the official said.

    A Kenyan official told Intellectual Property Watch that “we think we have achieved something” and that although it was not the best, the resolution is a “very good beginning.” “It was crucial that we managed to find each other,” the official said, and that all countries now “stand together.”

    The Kenyan official said that later when it comes to implementation it would become clear which countries are serious about the resolution. He added that the developing countries had fought to keep in the word “framework.”

    The Kenyan official commended the Swiss chair, saying that he had “captured people’s fears and aspirations.” In general there had been a “huge participation” among the delegates in the technical group. The chair was Gaudenz Silberschmidt of the Swiss Federal Office of Public Health.

    Some non-governmental participants have taken issue with the position of the European Commission on the resolutions, which they saw as too close to the position of the pharmaceutical industry (IPW, Public Health, 25 May 2006). A Commission representative told Intellectual Property Watch that he was not aware of undue influence by industry, but questions appear to remain.

    James Love of the Consumer Project on Technology, which was an early promoter of the idea, welcomed the outcome, giving special credit to Kenya and Brazil but also the United States.

    He said Brazil and Kenya had been “so strong in the negotiations” and showed such a devotion to the cause that it had “made everybody want it to work.”

    He said that the issue of intellectual property had been a “hot potato” particularly for the United States but the agreement means that there now is a “new paradigm for trade.”

    Love said that since January, the United States had showed support for the idea and had understood that the draft resolution on R&D was not an attack on the United States, which is the largest funder of R&D. It is in the US national interest that other countries participate more in research and development, Love said.

    Médecins Sans Frontières also welcomed what it called a “breakthrough” agreement. “For the first time, we’re starting to see action that begins to mirror the magnitude of the problems and needs that we witness everyday in our field programmes,” Dr. Tido von Schoen-Angerer, director of R&D at MSF’s Campaign for Access to Essential Medicines, said in a statement. “This is a crucial first step that will help put in place new ways of stimulating R&D for health problems that so far industry has ignored”

    Representatives of the pharmaceutical industry were unavailable for comment at press time.

     

    Comments

    1. Niclas says:

      Yippie! This just made my week, let’s hope the following work has the same cooperative touch to it and WTO can accept the need for WHO to have some influence over IP and TRIPS. And I’ll be questioning my swedish government to do their part for sure!

    2. Donald W. Light says:

      This call for action and a new strategy is great news, and anyone interested in thinking about what is possible might benefit from two short published reports.

      The first, in the BMJ, assembles evidence that pharmaceutical companies earn back all their R&D investments every year at European prices, with good profits; so that they could sell any patented drugs or vaccines to poorer countries for a fraction of Western prices and still make a modest profit on them. See Light DW and Lexchin, J. Foreign Free Riders and the High Prices of U.S. Patented Drugs. BMJ 2005; 331:958-60
      http://bmj.bmjjournals.com/cgi/search?loct=ehom&andorexactfulltext=and&resourcetype=1&disp_type=&sortspec=relevance&author1=&fulltext=&volume=331&firstpage=958

      The second is a re-analysis of the 10/90 Report that shows only 12 percent of research funds to discover new drugs or vaccines come from the pharmaceutical industry, and 84.2 percent come from the public. This implies that the main need is less to find more research money than to organize more of the public funds around the priorities of neglected diseases. See Light D. W. “Basic research funds to discover important new drugs: Who contributes how much?” Ch. 3 in Monitoring the Financial Flows for Health Research Behind the Global Numbers. The Global Forum for Health Research, 2006.
      http://www.globalforumhealth.org/Site/002__What%20we%20do/005__Publications/004__Resource%20flows.php

      Don Light


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.